Acute COVID-19-associated cardiovascular syndrome: state of the problem and clinical observation

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

A review of data on the impact of a new coronavirus infection, COVID-19, on cardiovascular diseases is presented. When treating patients, it is necessary to timely apply additional instrumental research methods, control biomarkers of myocardial damage, and reasonably prescribe medications.

Full Text

Restricted Access

About the authors

T. A. Zanegina

52th Consultative and Diagnostic Center of the Ministry of Defense of the Russian Federation

Author for correspondence.
Email: zaneginat@rambler.ru
Russian Federation, Moscow

L. E. Khachaturyan

52th Consultative and Diagnostic Center of the Ministry of Defense of the Russian Federation

Email: zaneginat@rambler.ru
Russian Federation, Moscow

O. I. Didenko

52th Consultative and Diagnostic Center of the Ministry of Defense of the Russian Federation

Email: zaneginat@rambler.ru
Russian Federation, Moscow

N. I. Pakhomova

52th Consultative and Diagnostic Center of the Ministry of Defense of the Russian Federation

Email: zaneginat@rambler.ru
Russian Federation, Moscow

E. S. Vitrenko

52th Consultative and Diagnostic Center of the Ministry of Defense of the Russian Federation

Email: zaneginat@rambler.ru
Russian Federation, Moscow

References

  1. Зайцев А.А., Савушкина О.И., Черняк А.В., Кулагина И.Ц., Крюков Е.В. Клинико-функциональная характеристика пациентов, перенесших новую коронавирусную инфекцию COVID-19 // Практич. пульмонол. – 2020. – № 1. – С. 78–81.
  2. Шляхто Е.В., Конради А.О., Арутюнов Г.П. и др. Руководство по диагностике и лечению болезней системы кровообращения в контексте пандемии COVID-19 // Рос. кардиол. журн. – Т. 25, № 3. – С. 129–148.
  3. Guo T., Fan Y., Chen M. et al. Cardiovascular Implications of Fatal Outcomes of Patients with Coronavirus Disease 2019 (COVID-19) // JAMA Cardiol. – 2020. – Vol. 5, N 7. – Р. 811–818. doi: 10.1001/jamacardio.2020.1017
  4. Gurwitz D. Angiotensin receptor blokers as tentative SARS-CoV-2 therapeutics // Drug. Dev. Res. – 2020. – Vol. 81, N 5.– Р. 537–540. doi: 10.1002/ddr.21656
  5. Huang C., Wang Y., Li X. et al. Сlinical features of patients infected with 2019 novel coronavirus in Wuhan, China // Lancet. – 2020. – Vol. 395. – P. 497–506. doi: 10.1016/S0140-6736(20)30183-5
  6. Inciardi R. M., Lupi L., Zaccone G. et al. Cardiac Involvement in a Patient with Coronavirus Disease 2019 (COVID-19) // JAMA Cardiol. – 2020. – Vol. 5, N 7. – Р. 819–824. doi: 10.1001/jamacardio.2020.1096
  7. Kwong J. C., Schwartz K. L., Campitelli M.A. et al. Acute Myocardial Infarction after Laboratory – Confirmed Influenza Infection // N. Engl. J. Med. – 2018. – Vol. 378, N 4. – P. 345–353. doi: 10.1056/NEJMoa1702090
  8. Li B., Yang J., Zhao F. et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China // Clin. Res. Cardiol. – 2020. – Vol. 109, N 5. – P. 531–538. DOI: 10. 1007/s00392-020-01626-9
  9. Long B., Brady W. J., Koyfman A., Gottlieb M. Cardiovascular complications in COVID-19 // Am. J. Emerg. Med. – 2020. – Vol. 38, N 7.– Р. 1504–1507. DOI: 10.1016/j. ajem.2020.04.048
  10. Mehra M. R., Desai S. S., Ruschitzka F., Patel A.N. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis // Lancet. – 2020. – Published Online May 22. DOI: https://doi.org/10.1016/S0140-6736(20) 31180-6
  11. Niu L., An X.-J., Tian J., Wang Y. 124 cases of clinical analysis of children with viral myocarditis // Eur. Rev. Med. Pharmacol. Sci. – 2015. – Vol. 19, N 15. – Р. 2856–2859.
  12. Oudit G.Y., Kassiri Z., Jiang C. et al. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS // Eur. J. Clin. Invest. – 2009. – Vol. 39, N 7. – P. 618–625. doi: 10.1111/j.1365–2362.2009.02153.x
  13. Ruan Q., Yang K., Wang W. et al. Correction to: Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China // Intens. Care Med. – 2020. – Vol. 46. – P. 1294–1297. doi: 10.1007/s00134-020-06028-z
  14. Shi S., Qin M., Shen B. et al. Association of Cardiac Injury with Mortality in Hospitalized Patients with COVID-19 in Wuhan, China // JAMA Cardiol. – 2020. – Vol. 5. – Р. 802–810. doi: 10.1001/jamacardio.2020.0950
  15. Wang D., Hu B., Hu C. et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected pneumonia in Wuhan, China // JAMA. – 2020. – Vol. 323, N 11. – P. 1061–1069. doi: 10.1001/jama.2020.1585
  16. Welt F.G.P., Shah P.B., Aronow H.D. et al. Catheterization Laboratory Considerations During the Coronavirus (COVID-19) Pandemic: From the ACC’s Interventional Council and SCAI // J. Am. Coll. Cardiol. – 2020. – Vol. 75, N 18. – Р. 2372–2375. doi: 10.1016/j.jacc. 2020.03.021
  17. Yang C., Jin Z. An Acute Respiratory Infection Runs Into the Most Common Noncommunicable Epidemic – COVID-19 and Cardiovascular Diseases // JAMA Cardiol. – 2020. – Vol. 5, N 7.– Р. 743–744. doi: 10.1001/jamacardio.2020.0934
  18. Zhou F., Yu T., Du R. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study // Lancet. – 2020. – Vol. 395, Iss. 10229. – P. 1054–1062. doi: 10.1016/S0140-6736(20)30566-3

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2023 Zanegina T.A., Khachaturyan L.E., Didenko O.I., Pakhomova N.I., Vitrenko E.S.


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: № 01975 от 30.12.1992.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies